CY1114523T1 - Μεθοδοι για τη θεραπεια των συναισθηματικων διαταραχων - Google Patents

Μεθοδοι για τη θεραπεια των συναισθηματικων διαταραχων

Info

Publication number
CY1114523T1
CY1114523T1 CY20131100922T CY131100922T CY1114523T1 CY 1114523 T1 CY1114523 T1 CY 1114523T1 CY 20131100922 T CY20131100922 T CY 20131100922T CY 131100922 T CY131100922 T CY 131100922T CY 1114523 T1 CY1114523 T1 CY 1114523T1
Authority
CY
Cyprus
Prior art keywords
tmeff2
regulator
treatment
compound
identifying
Prior art date
Application number
CY20131100922T
Other languages
English (en)
Inventor
Marcelo Paez-Pereda
Marta Labeur
Original Assignee
Phenoquest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenoquest Ag filed Critical Phenoquest Ag
Publication of CY1114523T1 publication Critical patent/CY1114523T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια μέθοδο για την αναγνώριση ενός ρυθμιστή της ΤΜΕFF2, που περιλαμβάνει (α) την επαφή ενός κυττάρου που εκφράζει την ΤΜΕFF2 με μια υποψήφια ένωση που πρόκειται να ελεγχθεί, (β) τη μέτρηση σχετικά με το αν η αναφερθείσα ένωση που πρόκειται να ελεγχθεί μειώνει ή αυξάνει το επίπεδο ενός συστατικού της οδού σήμανσης της cAMP, κατά προτίμηση της οδού σήμανσης της CRΗ, στο αναφερθέν κύτταρο όταν συγκρίνεται με ένα αντίστοιχο κύτταρο το οποίο δεν εκφράζει την ΤΜΕFF2, (β') τον προαιρετικό προσδιορισμό σχετικά με το αν η αναφερθείσα ένωση έχει τη δυνατότητα να μειώνει τη δέσμευση ανάμεσα στην Ακτιβίνη και την ΤΜΕFF2, και (γ) την αναγνώριση της αναφερθείσας ρυθμιστικής ένωσης. Επιπλέον, εξετάζεται μια μέθοδος για την αναγνώριση ενός ρυθμιστή της ΤΜΕFF2 που περιλαμβάνει τον προσδιορισμό σχετικά με το αν ο αναφερθείς ρυθμιστής της ΤΜΕFF2 έχει τη δυνατότητα να μειώνει τη δέσμευση ανάμεσα στην Ακτιβίνη και την ΤΜΕFF2. Αναφέρεται επίσης σε χρήσεις και μεθόδους που εφαρμόζουν έναν αγωνιστή της ΤΜΕFF2 για τη θεραπεία Συνδρόμων Cushing και ένα ρυθμιστή της ΤΜΕFF2 για τη θεραπεία συναισθηματικών διαταραχών. Επιπλέον, παρέχονται μέθοδοι διάγνωσης συναισθηματικών διαταραχών ή Συνδρόμων Cushing.
CY20131100922T 2006-02-07 2013-10-21 Μεθοδοι για τη θεραπεια των συναισθηματικων διαταραχων CY1114523T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06002474 2006-02-07
EP07703327.2A EP1982178B1 (en) 2006-02-07 2007-02-07 Methods for the treatment of affective disorders

Publications (1)

Publication Number Publication Date
CY1114523T1 true CY1114523T1 (el) 2016-10-05

Family

ID=38066498

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100922T CY1114523T1 (el) 2006-02-07 2013-10-21 Μεθοδοι για τη θεραπεια των συναισθηματικων διαταραχων

Country Status (8)

Country Link
US (1) US8153127B2 (el)
EP (1) EP1982178B1 (el)
CY (1) CY1114523T1 (el)
DK (1) DK1982178T3 (el)
ES (1) ES2435793T3 (el)
PL (1) PL1982178T3 (el)
PT (1) PT1982178E (el)
WO (1) WO2007090631A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937161B2 (en) * 2007-10-19 2015-01-20 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
EP3096756A1 (en) 2014-01-21 2016-11-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CN114711192B (zh) * 2022-04-13 2022-11-29 中国科学院西北高原生物研究所 一种长效抑郁症动物模型的构建试剂盒及构建方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법

Also Published As

Publication number Publication date
DK1982178T3 (da) 2013-09-08
US20100069463A1 (en) 2010-03-18
EP1982178A1 (en) 2008-10-22
EP1982178B1 (en) 2013-07-24
US8153127B2 (en) 2012-04-10
WO2007090631A1 (en) 2007-08-16
PT1982178E (pt) 2013-10-24
ES2435793T3 (es) 2013-12-23
PL1982178T3 (pl) 2014-02-28

Similar Documents

Publication Publication Date Title
CY1116584T1 (el) Ανθρωπινα αυτοαντισωματα αντι-αλφα-συνουκλεϊνης
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
CY1118406T1 (el) Μεθοδοι αγωγης συνδρομου down, συνδρομου ευθραυστου χ και αυτισμου
EA201170323A1 (ru) Антитела против il-12/il-23
BRPI0715126B8 (pt) métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
DK2129391T3 (da) Diagnostisk fremgangsmåde
CY1112456T1 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
CY1114523T1 (el) Μεθοδοι για τη θεραπεια των συναισθηματικων διαταραχων
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
EP3734280A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112017025051A2 (pt) ensaio celular para detecção de homodímeros anti-cd3
ATE493290T1 (de) Alcotestgerät
DE60228557D1 (de) Candida-nachweis
DE602005015559D1 (de) Pharmakodynamische tests mit durchflusszytometrie
DK2155185T4 (da) Påvisning af succinylacetone
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2006124526A3 (en) Method for assessing the effectiveness of a treatment regimen by determining zonulin
BR112016017926A2 (pt) ensaio para detectar periostina humana
WO2009108170A3 (en) Compositions and methods for determining immune status
ATE488772T1 (de) Biomarker zur beurteilung der leberfunktion
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
DE102005051976A1 (de) Kit für hoch-sensitive Nachweisassays
ATE528651T1 (de) Diagnoseverfahren für pulmonale arterielle hypertonie